by Maria Zannes | May 3, 2017 | Press Releases
MAY 3, 2017 (SAN ANTONIO, TX ) bioAffinity Technologies announced that the European Patent Office (EPO) has issued a patent that protects the Company’s proprietary CyPath® technology for the early detection of lung cancer through 2030. The EPO patent, titled “System...
by Maria Zannes | Nov 15, 2016 | Press Releases
NOVEMBER 15, 2016 (SAN ANTONIO, TX) bioAffinity Technologies announced that the government of the Hong Kong Special Administrative Region has awarded a Certificate of Grant of Standard Patent for the Company’s proprietary CyPath© technology for the early detection of...
by Maria Zannes | Aug 24, 2016 | Press Releases
AUGUST 24, 2016 (SAN ANONIO, TX) bioAffinity Technologies today announced that it has been awarded a U.S. Patent protecting a proprietary kit that contains the CyPath® assay for the early detection of cancer and the prognosis of the patient response to cancer therapy....
by Maria Zannes | Jul 13, 2016 | Press Releases
JULY 13, 2016 (SAN ANTONIO, TX) bioAffinity Technologies today announced the renewal of its collaborative agreement with The University of Texas Health Science Center at San Antonio for research and development of novel cancer diagnostic and therapeutic agents using...
by Maria Zannes | Jul 7, 2016 | Press Releases
JULY 7, 2016 (SAN ANTONIO, TX) bioAffinity Technologies today announced that William Bauta, Ph.D., will join the company in September 2016 as Senior Vice President for Research and Development, Therapeutics. Dr. Bauta will direct the development and commercialization...
by Maria Zannes | Jun 23, 2016 | Press Releases
JUNE 23, 2016 (SAN ANTONIO, TX ) bioAffinity Technologies today announced the formation of OncoSelect Therapeutics, LLC, a subsidiary company that will leverage bioAffinity’s proprietary porphyrin-based diagnostic technology to target a variety of cancers for...
